The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Challenges of selecting frontline therapy in CLL
Jacqueline Barrientos, MD, MS, Feinstein Institute for Medical Research, Manhasset, NY, outlines the challenges associated with choosing the most appropriate therapeutic regimen for the treatment of chronic lymphocytic leukemia (CLL) in a rapidly evolving field. In particular, Dr Barrientos discusses the advantages and disadvantages of BTK inhibitor therapies, such as ibrutinib and acalabrutininb, compared to fixed-duration BCL-2 inhibitor therapy in combination with obinutuzumab. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Jacqueline Barrientos, MD, MS, has received research funding from AstraZeneca, Oncternal, TG therapeutics and Pharmacyclics/Abbvie; and has participated in advisory boards for AstraZeneca, Pharmacyclics/Abbvie, Beigene, Genentech, Gilead and Innate.
